{"nctId":"NCT01717742","briefTitle":"Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)","startDateStruct":{"date":"2012-12"},"conditions":["Pleural Empyema"],"count":97,"armGroups":[{"label":"tPA and placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TPA (Tissue Plasminogen Activator)","Other: Placebo"]},{"label":"tPA and DNase","type":"EXPERIMENTAL","interventionNames":["Drug: TPA (Tissue Plasminogen Activator)","Drug: DNase"]}],"interventions":[{"name":"TPA (Tissue Plasminogen Activator)","otherNames":["Cathflo (alteplase, recombinant)"]},{"name":"DNase","otherNames":["Pulmozyme (Dornase alfa)"]},{"name":"Placebo","otherNames":["Normal saline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. age 6 months to 18 years\n2. hospitalized with diagnosis of pleural empyema requiring chest tube drainage with fibrinolytics as judged by the attending physician with the following criteria:\n\n   1. pneumonia with pleural effusion as documented on ultrasound of the chest; AND\n   2. need for further intervention in addition to antibiotics based on clinical criteria \\[persistent fever despite on antibiotics for at least 48 hours OR significant respiratory distress tachypnea, hypoxia) as a result of the pleural fluid collection\\]\n\nExclusion Criteria:\n\n1. empyema as a result of tuberculosis, fungus or non-infectious causes (e.g. malignancy)\n2. known coagulation impairment\n3. suspected or proven allergy to tPA or DNase\n4. chronic lung disease or other chronic illnesses (e.g. immunodeficiency or neurologic impairment)\n5. child has already undergone a drainage procedure (e.g. chest drain or VATS).\n6. recent administration of an investigational drug (within previous 30 days)\n7. pregnancy\n8. breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Hospital Discharge","description":"Time from insertion of the chest drain to discharge from hospital.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"4.9"},{"groupId":"OG001","value":"9.1","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Time to Meeting Discharge Criteria","description":"Time from insertion of the chest drain to meeting discharge criteria.\n\nDischarge criteria:\n\n* Chest tube removed\n* No fever \\[temperature less than 38Â°C\\]\n* Normal respiratory rate forage\n* No hypoxia\n* Drinking fluids wel","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"4.5"},{"groupId":"OG001","value":"8.5","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Time to Drain Removal","description":"Time from drain insertion to drain removal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"4.3"},{"groupId":"OG001","value":"6.9","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Duration of Fever After Intervention","description":"Duration of fever (defined as temperature \\>38 degrees celsius taken by any method) from insertion of the chest drain until resolution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"3.4"},{"groupId":"OG001","value":"3.3","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Need for Ventilatory Support or Non-invasive Ventilation Following the Intervention","description":"Number of Participants with need for any kind of ventilatory support or any kind of non-invasive ventilation right after the intervention.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Bleeding","description":"Number of Participants who had intrapleural bleeding resulting in a drop in hemoglobin of greater than 20 g/L or needing a transfusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Further Interventions","description":"Number of participants who needed further intervention such as placement of another chest drain (by any technique) or surgical intervention such as thoracotomy and decortication, video-assisted thorascopic surgery, or pneumonectomy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hospital Readmission","description":"Number of Participants who had any hospital readmission after discharge from hospital for initial treatment for pleural empyema within three months related to pleural empyema or its treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cost of the Hospitalization","description":"An economic evaluation will compare the relative costs of DNase-tPA with tPA alone in previously well children who present with pleural empyema, using patient-level data from the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11329","spread":"7139"},{"groupId":"OG001","value":"10760","spread":"5071"}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"Mortality from any cause during the hospitalization for empyema.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Chest Radiography","description":"The radiograph closest to the time of drain removal will be reviewed by a blinded study radiologist to determine the percentage of hemithorax occupied using a 5 point ordinal scale utilized in previous studies ranging from no fluid present to fluid occupying \\>75% of the most affected hemithorax.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":49},"commonTop":["Constipation","Nausea","Rash","Edema","Low albumin"]}}}